奥氮平与奋乃静治疗脑血管病伴发精神障碍对照研究

目的探讨奥氮平与奋乃静治疗急性脑血管病伴发精神障碍的临床疗效和安全性。方法将80例急性脑血管病伴发精神障碍患者随机分为奋乃静和奥氮平组各40例，进行双盲对照治疗，观察4w。于治疗前及治疗2w、4w末采用临床总体印象量表评定临床疗效，副反应量表评定不良反应。结果治疗2w末，奥氮平组有效率为75．0％，奋乃静组为25．0％，两组差异有极显著性（χ^2=20．0，P〈0．01）；4w末奥氮平组有效率为90％，奋乃静组为80％，两组差异无显著性（P〉0．05）。奥氮平组不良反应发生率为20．0％，奋乃静组为52．5％，两组差异有极显著性（χ^2=12．8，P〈0．05）。结论奥氮平治疗急性脑血管病伴发精神障碍较奋乃静治疗起效快、安全性高，依从性好。

A control study of olanzapine and perphenazine in the treatment of cerebrovascular diseases with mental disorders

Objective To compare the curative effects and safety of olanzapine and perphenazine in the treatment of acute cerebrovaseular disorders with mental disorders. Methods 80 patients without system treatment were randomly divided into perphenazine and olanzapine group （each n = 40） receiving doubleblind controlled treatment. Severity was assessed with the Brief Psychiatric Symptom Rating Scale （BPRS）, curative effects with the Clinical Global Impression （CGI SI） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the ends of the 2^nd and 4^th week treatment. Results At the end of the 2^nd week, efficacy was significantly higher in the olanzapine than in the （P〈0.05 or 0.01）; perphenazine began excellence at the end of the 4^th week; there was no significant difference in total efficacy between the 2 groups at the end of the 8^th week（P〉0.05）. Olanzapine adverse reactions were milder. Conclusion Olanzapine soon take effect and has fewer adverse reactions in the treatment of acute cerebral vascular diseases with mental disorders.